Ptc Therapeutics (PTCT) Receivables - Net (2016 - 2025)
Ptc Therapeutics (PTCT) has 13 years of Receivables - Net data on record, last reported at $181.6 million in Q4 2025.
- For Q4 2025, Receivables - Net rose 14.55% year-over-year to $181.6 million; the TTM value through Dec 2025 reached $181.6 million, up 14.55%, while the annual FY2025 figure was $181.6 million, 14.55% up from the prior year.
- Receivables - Net reached $181.6 million in Q4 2025 per PTCT's latest filing, down from $203.1 million in the prior quarter.
- Across five years, Receivables - Net topped out at $210.5 million in Q1 2025 and bottomed at $78.8 million in Q2 2021.
- Average Receivables - Net over 5 years is $158.9 million, with a median of $163.3 million recorded in 2023.
- Peak YoY movement for Receivables - Net: skyrocketed 78.86% in 2021, then decreased 2.08% in 2024.
- A 5-year view of Receivables - Net shows it stood at $110.5 million in 2021, then skyrocketed by 40.88% to $155.6 million in 2022, then increased by 3.35% to $160.8 million in 2023, then dropped by 1.41% to $158.6 million in 2024, then grew by 14.55% to $181.6 million in 2025.
- Per Business Quant database, its latest 3 readings for Receivables - Net were $181.6 million in Q4 2025, $203.1 million in Q3 2025, and $196.1 million in Q2 2025.